Second Joint Working Conference: National Cancer Institute Chemotherapy Program. Working session report: pharmacology.
D000470:Alkaloids / Q000378:metabolism / Q000627:therapeutic use; D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001345:Autoradiography; D001374:Azacitidine / Q000378:metabolism / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use; D002247:Carbon Isotopes; D002460:Cell Line / Q000187:drug effects; D002478:Cells, Cultured / Q000187:drug effects; D006224:Cricetinae; D003561:Cytarabine / Q000494:pharmacology / Q000627:therapeutic use; D004247:DNA / Q000096:biosynthesis; D004254:DNA Nucleotidyltransferases / Q000037:antagonists & inhibitors; D004285:Dogs; D006207:Half-Life; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy; D008168:Lung / Q000187:drug effects; D011725:Pyridines / Q000627:therapeutic use; D012313:RNA / Q000096:biosynthesis
D000470:Alkaloids; D000963:Antimetabolites; D000970:Antineoplastic Agents; D002227:Carbazoles; D002247:Carbon Isotopes; D011725:Pyridines; D003561:Cytarabine; D012313:RNA; D004247:DNA; D004254:DNA Nucleotidyltransferases; D001374:Azacitidine